Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pevonedistat plus azacitidine versus azacitidine alone in higher-risk MDS, CMML, and low-blast AML
NL-OMON45865Phase 2Active, not recruiting
- Sponsor
- Millennium Pharmaceuticals
- Start
- Jun 2016
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) comparing Pevonedistat + azacitidine with Azacitidine (2 arms). Primary endpoint: Event-free survival. Started Jun 2016; status: active, not recruiting.
02
Drugs
pevonedistatazacitidine
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON45865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45865.